Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
cancer
8
×
life sciences
national blog main
8
×
national top stories
8
×
new york blog main
startups
8
×
biotech
boston top stories
detroit blog main
detroit top stories
new york top stories
raleigh-durham blog main
raleigh-durham top stories
san diego blog main
san diego top stories
san francisco blog main
san francisco top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
wisconsin blog main
wisconsin top stories
boulder/denver blog main
boulder/denver top stories
indiana blog main
indiana top stories
national
deals
europe blog main
europe top stories
fda
alzheimer's disease
clinical trials
eli lilly
ipo
novartis
takeda pharmaceutical
abbvie
What
bio
roundup
life
medicines
sciences
years
acquisitions
ago
build
buy
ceo
companies
covid
daniel
debut
drugs
gilead
ipo
moves
new
o’day
pipeline
science
therapeutics
week
activity
adding
admits
aiming
alliance
announced
approvals
bails
balance
big
biggest
biogen
biotechs
black
brand
Language
unset
8
×
Current search:
startups
×
unset
×
" national blog main "
×
" national top stories "
×
cancer
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
3 years ago
Bio Roundup: SeaGen Scores, Dyne’s Debut, Microbiome Moves & More
@xconomy.com
4 years ago
Bio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
@xconomy.com
4 years ago
Bio Roundup: Gilead’s $4.9B Deal, COVID-19 Collabs, IPO Plans & More
@xconomy.com
4 years ago
Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More
@xconomy.com
4 years ago
Decibel Therapeutics Strikes a Balance, Adding Regenerative Med Focus
@xconomy.com
4 years ago
Bio Roundup: Ichnos Emerges, Beyond CAR-T, BridgeBio Bails & More
@xconomy.com
4 years ago
Five Years After Y Combinator First Admits Biotechs, They’re Dug In